MARINUS PHARMACEUTICALS INC (MRNS) Stock Price, Quote, News and Overview
NASDAQ:MRNS - Nasdaq - US56854Q2003 - Common Stock - Currency: USD
MRNS Quote, Performance and Key Statistics
0.55
+0 (+0.09%)
The current stock price of MRNS is 0.55 USD. In the past month the price increased by 2.42%. In the past year, price decreased by -94.48%.
MRNS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.89 | 824.51B | ||
| JNJ | JOHNSON & JOHNSON | 16.69 | 401.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.18 | 386.95B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.41 | 240.28B | ||
| MRK | MERCK & CO. INC. | 12.39 | 239.09B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.56 | 228.26B | ||
| PFE | PFIZER INC | 8.59 | 151.49B | ||
| SNY | SANOFI-ADR | 14.24 | 148.55B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 53.59 | 123.97B | ||
| GSK | GSK PLC-SPON ADR | 8.29 | 81.62B | ||
| ZTS | ZOETIS INC | 28.78 | 76.29B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.71 | 47.88B |
Related stock screener links
About MRNS
Company Profile
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The company went IPO on 2014-07-31. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Company Info
MARINUS PHARMACEUTICALS INC
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd
Radnor PENNSYLVANIA 19087 US
CEO: Scott Braunstein
Employees: 165
Company Website: https://marinuspharma.com/
Investor Relations: https://ir.marinuspharma.com
Phone: 14848014670
MARINUS PHARMACEUTICALS INC / MRNS FAQ
What is the stock price of MARINUS PHARMACEUTICALS INC today?
The current stock price of MRNS is 0.55 USD. The price increased by 0.09% in the last trading session.
What is the ticker symbol for MARINUS PHARMACEUTICALS INC stock?
The exchange symbol of MARINUS PHARMACEUTICALS INC is MRNS and it is listed on the Nasdaq exchange.
On which exchange is MRNS stock listed?
MRNS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MARINUS PHARMACEUTICALS INC stock?
13 analysts have analysed MRNS and the average price target is 1.09 USD. This implies a price increase of 97.82% is expected in the next year compared to the current price of 0.55. Check the MARINUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MARINUS PHARMACEUTICALS INC worth?
MARINUS PHARMACEUTICALS INC (MRNS) has a market capitalization of 30.37M USD. This makes MRNS a Nano Cap stock.
How many employees does MARINUS PHARMACEUTICALS INC have?
MARINUS PHARMACEUTICALS INC (MRNS) currently has 165 employees.
What are the support and resistance levels for MARINUS PHARMACEUTICALS INC (MRNS) stock?
MARINUS PHARMACEUTICALS INC (MRNS) has a support level at 0.55 and a resistance level at 0.56. Check the full technical report for a detailed analysis of MRNS support and resistance levels.
Is MARINUS PHARMACEUTICALS INC (MRNS) expected to grow?
The Revenue of MARINUS PHARMACEUTICALS INC (MRNS) is expected to grow by 9.81% in the next year. Check the estimates tab for more information on the MRNS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MARINUS PHARMACEUTICALS INC (MRNS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRNS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRNS, evaluating the profitability, health, valuation and growth aspects
- MARINUS PHARMACEUTICALS INC (MRNS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MARINUS PHARMACEUTICALS INC (MRNS) Sales and EPS estimates to see what analysts future expectations are.
- MARINUS PHARMACEUTICALS INC (MRNS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MARINUS PHARMACEUTICALS INC (MRNS) Insider and Institutional Ownership to learn about the owners and their transactions.
- MARINUS PHARMACEUTICALS INC (MRNS) Stock Chart to make your own analysis
- MARINUS PHARMACEUTICALS INC (MRNS) Latest news and press-releases to stay up to date.
Does MARINUS PHARMACEUTICALS INC (MRNS) stock pay dividends?
MRNS does not pay a dividend.
When does MARINUS PHARMACEUTICALS INC (MRNS) report earnings?
MARINUS PHARMACEUTICALS INC (MRNS) will report earnings on 2025-03-11, after the market close.
What is the Price/Earnings (PE) ratio of MARINUS PHARMACEUTICALS INC (MRNS)?
MARINUS PHARMACEUTICALS INC (MRNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).
MRNS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MRNS. When comparing the yearly performance of all stocks, MRNS is a bad performer in the overall market: 72.37% of all stocks are doing better.
MRNS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRNS. MRNS has a bad profitability rating. Also its financial health evaluation is rather negative.
MRNS Financial Highlights
Over the last trailing twelve months MRNS reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 7.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRNS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to MRNS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 19.91% and a revenue growth 9.81% for MRNS